查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010930

肾癌治疗市场：2026-2032年全球市场预测（按癌症类型、治疗方法、给药途径、剂型和最终用户划分）

Kidney Cancer Drugs Market by Cancer Type, Treatment Type, Route Of Administration, Dosage Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肾癌治疗市场价值将达到 65.1 亿美元，到 2026 年将成长至 68.9 亿美元，到 2032 年将达到 99 亿美元，复合年增长率为 6.16%。

主要市场统计数据
基准年 2025 65.1亿美元
预计年份：2026年 68.9亿美元
预测年份 2032 99亿美元
复合年增长率 (%) 6.16%

对肾癌治疗市场进行关键概述，重点在于科学进步、临床实践变化以及对相关人员的策略影响。

肾癌治疗的现状正进入一个快速发展的时期，这段时期涵盖了科学、临床和商业性多个方面，其驱动力来自生物学的突破性进展、临床实践的改进以及支付方趋势的转变。免疫肿瘤学和标靶治疗的进步正在重塑治疗模式，催生出新的治疗方法组合和治疗顺序策略。这些都需要临床医生、支付方和产业负责人认真考虑。同时，以患者为中心的因素，例如耐受性、给药便利性和生活质量，也日益影响治疗方法选择和研发的优先顺序。

精准医疗、免疫肿瘤学的进步以及真实世界数据（REW）的整合如何全面重塑治疗方法选择和商业化策略。

随着精准医疗、免疫肿瘤学进展和联合治疗的融合，肾癌治疗格局正在发生变革性转变，重新定义了治疗标准。新型分子标靶疗法越来越多地基于分子谱分析，从单一的治疗方案转向以生物标记主导的干预，旨在最大限度地提高疗效并最大限度地降低毒性。同时，包括查核点抑制剂和新型免疫调节剂在内的免疫疗法策略日益成熟，正在扩大特定患者群体中持续缓解的范围，并推动探索协同联合治疗的新型临床试验。

我们评估了近期关税变化对营运程序和准入的影响，以及製造和筹资策略的韧性如何减轻这种干扰。

国家层级的政策变化会对药品供应链、定价策略和市场进入连锁反应，而近期关税趋势也对药品采购、生产和分销领域的相关人员带来了新的复杂性。跨境贸易成本会影响筹资策略和策略采购决策，迫使製造商重新评估製造地、在地采购方案和库存策略，以防止供应中断并维持经济竞争力。

基于细分的详细见解，展示了癌症亚型、治疗方法、剂型和临床环境如何决定临床开发和商业化途径。

细分市场分析凸显了治疗药物开发和商业化策略需要根据每种癌症类型、治疗方法、给药途径、剂型和最终用户的独特临床特征和递送特性进行客製化。基于癌症类型，肾细胞癌、肾肉瘤、移行细胞癌和威尔姆氏肿瘤的治疗方案和临床试验设计有显着差异。每种适应症都有其独特的生物学因素、患者群体和临床终点，这些因素会影响监管策略和临床推广途径。因此，申办方应制定与每种癌症亚型的自然病程和未满足的医疗需求相符的实证方案。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、支付方期望和临床基础设施都会对药物的可及性和商业化产生影响。

区域趋势对临床试验参与者招募、监管方式、定价预期和医疗服务模式均有显着影响，因此，深入了解区域差异对于制定全球策略至关重要。在美洲，多样化的支付模式和对创新的高度重视影响着新治疗方法的发展轨迹，该地区产生的真实世界数据往往反映在支付方的决策和指南更新中。此外，主要学术研究中心的集中也为早期临床试验活动提供了支持，并有助于快速评估有前景的联合治疗和生物标记。

加速创新肾癌疗法的开发、全球推广和普及的企业策略方法和合作模式。

企业层面的发展趋势反映了各公司不同的策略立场，从专注于生物製剂的专业公司到致力于建构整合肿瘤产品组合的多元化製药公司，不一而足。主要企业倾向于集中投资于联合疗法、生物标记主导的适应症以及旨在向支付方证明可持续临床获益和成本效益的真实世界研究项目。同时，中型和新兴企业则经常致力于开发小众适应症和创新给药平台，以建立差异化的价值提案，并吸引策略合作伙伴关係和授权授权机会。

产业领导者应采取切实可行的策略步骤，协调生物标记开发、证据产生、供应弹性和商业性执行，以产生持久的影响。

行业领导者应采取多管齐下的策略，将科学重点与切实可行的商业化和市场准入策略相结合，以快速将有前景的治疗方法转化为永续的临床应用。首先，经营团队必须优先考虑以生物标记主导的研发，并投资于伴随诊断，以确保患者选择策略稳健且具有临床可行性。这种策略的结合能够降低研发风险，并透过在特定患者群体中证实标靶化获益，增强医保报销的证据。

采用以证据主导的调查方法，结合文献整合、专家咨询、真实世界资料审查和严格的基于情境的分析来检验结果。

本报告的研究结合了多来源证据架构和严谨的分析方法，以确保得出全面且可重复的结论。主要资料输入包括对同侪审查的临床文献、监管决策和指导文件的系统性回顾，并辅以对真实世界证据来源的检验和对临床实践模式的分析。透过整合这些要素，我们揭示了治疗方法的演变、临床应用趋势以及对研发和商业化营运的影响。

结论强调，需要将创新科学与严谨的商业化和在地化策略结合，以改善患者的治疗效果。

总之，肾癌治疗领域呈现出快速创新、治疗模式转变以及日益重视具有显着临床和经济价值的证据等特征。标靶治疗和免疫肿瘤学的进步正在拓展多种肾癌的治疗选择，而给药方式的演变和医疗服务模式的转变也持续影响着治疗方案的采纳。同时，供应链的韧性以及区域监管差异等运作因素对于确保患者获得治疗和维持治疗的连续性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以癌症类型分類的肾癌治疗市场

  • 肾臟细胞癌
  • 肾臟肉瘤
  • 移行细胞癌
  • 威尔姆氏肿瘤

第九章：肾癌治疗市场（依治疗方法划分）

  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 新治疗方法
  • 标靶治疗

第十章：肾癌治疗市场：依给药途径划分

  • 静脉注射
  • 口服

第十一章：肾癌治疗药物市场（依剂型划分）

  • 胶囊
  • 注射药物
  • 药片

第十二章：肾癌治疗市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章：肾癌治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：肾癌治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 肾癌治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肾癌治疗市场

第十七章：中国肾癌治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agensys, Inc.
  • Aravive, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • AVEO Pharmaceuticals, Inc.（an LG Chem company）
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Cytokinetics, Incorporated
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Ipsen SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Peloton Therapeutics, Inc.（a Merck & Co., Inc. company）
  • Pfizer Inc.
  • Roche Holding AG（F. Hoffmann-La Roche Ltd）
  • Surface Oncology, Inc.
Product Code: MRR-434CCDA0527F

The Kidney Cancer Drugs Market was valued at USD 6.51 billion in 2025 and is projected to grow to USD 6.89 billion in 2026, with a CAGR of 6.16%, reaching USD 9.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.51 billion
Estimated Year [2026] USD 6.89 billion
Forecast Year [2032] USD 9.90 billion
CAGR (%) 6.16%

A focused overview of the kidney cancer therapeutics landscape that frames scientific advances, clinical practice shifts, and strategic implications for stakeholders

The kidney cancer therapeutics landscape has entered a period of rapid scientific, clinical, and commercial evolution driven by breakthroughs in biology, refinements in clinical practice, and shifting payer dynamics. Advances in immuno-oncology and targeted agents have reframed treatment paradigms, creating new therapeutic combinations and sequencing strategies that demand careful scrutiny from clinicians, payers, and industry strategists. At the same time, patient-centric considerations such as tolerability, administration convenience, and quality of life are increasingly influencing therapeutic choice and development priorities.

As stakeholders navigate this complex environment, the interplay between regulatory decisions, real-world evidence generation, and commercial access pathways becomes critical. Regulatory authorities are adapting approval frameworks to accommodate novel mechanisms of action and accelerated pathways, while clinicians and multidisciplinary care teams are integrating evolving evidence into practice. Consequently, industry players must balance scientific innovation with pragmatic commercialization tactics that address real-world treatment patterns and system-level constraints. Transitioning from discovery to sustainable adoption therefore requires cross-functional alignment and foresight.

Ultimately, the introduction establishes a foundation for deeper analysis by outlining the primary drivers of change, the emerging therapeutic classes reshaping care, and the strategic imperatives that will define competitive advantage over the coming years. The intent is to orient readers toward the high-impact themes that warrant focused attention when assessing pipeline prioritization, partnership opportunities, and patient-access strategies.

How precision medicine, immuno-oncology progress, and real-world evidence integration are collectively reshaping therapeutic choices and commercialization strategies

The therapeutic landscape for kidney cancer is undergoing transformative shifts as precision medicine, immuno-oncology advances, and combination regimens converge to redefine standards of care. Emerging targeted therapies are increasingly informed by molecular profiling, prompting a move away from one-size-fits-all approaches toward biomarker-driven interventions that seek to maximize efficacy while mitigating toxicity. Concurrently, the maturation of immunotherapeutic strategies, including checkpoint inhibition and novel immune modulators, is expanding the range of durable responses for subsets of patients and prompting new trials that explore synergistic combinations.

In addition, the route and convenience of administration are catalyzing change; oral targeted agents and alternative dosing strategies are influencing patient adherence and site-of-care considerations. Parallel to clinical innovations, regulatory frameworks and reimbursement pathways are adapting to accommodate therapies with complex benefit-risk profiles, which in turn influences sponsor development strategies and post-approval evidence generation. Moreover, real-world data and patient-reported outcomes are playing an expanded role in demonstrating value and informing guideline updates.

These shifts collectively create opportunities for differentiation through combination science, companion diagnostics, and targeted real-world outcomes programs. For industry leaders, the imperative is to align scientific development with pragmatic access planning, invest in evidence-generation that resonates with payers and clinicians, and prepare organizational capabilities to support increasingly personalized treatment paradigms.

Assessing the practical operational and access ramifications of recent tariff shifts and how resilient manufacturing and procurement strategies can mitigate disruption

Policy changes at the national level can have cascading effects across pharmaceutical supply chains, pricing strategies, and market access efforts, and recent tariff dynamics have added a new layer of complexity for stakeholders involved in drug sourcing, manufacturing, and distribution. Cross-border trade costs have the potential to influence procurement strategies and strategic sourcing decisions, prompting manufacturers to reassess manufacturing footprints, local sourcing options, and inventory strategies to maintain uninterrupted supply and competitive economics.

As a result, companies with integrated manufacturing and diversified supplier bases are better positioned to absorb tariff-driven cost pressures, while smaller players may face heightened operational strain. In addition, health systems and specialty pharmacies that manage complex biologic and small-molecule therapeutics may need to adapt contracting practices and inventory management to preserve affordability and continuity of care. From a strategic perspective, organizations should prioritize supply chain visibility, scenario planning, and dialogue with payers to manage reimbursement impacts that arise indirectly from increased product costs.

Moving forward, coordinated planning across commercial, legal, and operations teams will be critical to mitigate tariff-related disruptions. Emphasizing resilience through nearshoring, dual sourcing, and flexible manufacturing can reduce exposure, while transparent stakeholder communication helps to preserve trust among clinicians and patients. Ultimately, integrating tariff considerations into strategic planning reduces execution risk and supports sustainable access to essential therapies.

Detailed segmentation-led insight showing how cancer subtype, treatment modality, route, dosage form, and care setting determine clinical development and commercialization pathways

Segmentation insights reveal that therapeutic development and commercialization strategies must be tailored to the distinct clinical and delivery characteristics of each cancer type, treatment modality, route of administration, dosage form, and end user. Based on Cancer Type, therapeutic programs and clinical trial designs differ markedly across Renal Cell Carcinoma, Renal Sarcoma, Transitional Cell Carcinoma, and Wilms Tumor, with each indication presenting unique biological drivers, patient demographics, and clinical endpoints that influence regulatory strategy and clinical adoption pathways. Consequently, sponsors should design evidence-generation plans that align with the natural history and unmet needs of each cancer subtype.

Based on Treatment Type, differentiation hinges on modality-specific considerations. Chemotherapy and hormone therapy retain roles in specific contexts, while immunotherapy and targeted therapy are increasingly central to treatment algorithms. Within immunotherapy, Checkpoint Inhibitors represent a pivotal class, and these agents further diverge into subcategories such as Cytokines and PD-1 Inhibitors, each carrying distinct mechanisms, toxicity profiles, and monitoring needs. Novel therapies, including cell-based and precision targeted constructs, introduce additional complexity in manufacturing and delivery that must be addressed early in development planning.

Based on Route Of Administration, the distinction between Intravenous and Oral delivery drives patient preference, site-of-care economics, and adherence considerations. Oral agents can shift therapy from infusion centers to outpatient management, altering payer mix and convenience for patients, whereas intravenous therapies may require infrastructure and resourcing at infusion sites. Based on Dosage Form, formulation decisions between Capsule, Injection, and Tablet affect pharmacokinetics, patient experience, and cold chain requirements. Finally, based on End User, differences among Ambulatory Surgical Centers, Hospitals, and Specialty Clinics shape contracting, reimbursement, and logistics. Integrating these segmentation dimensions into product development and commercial planning enables more precise targeting of clinical programs, reimbursement strategies, and provider engagement efforts.

How regional regulatory variance, payer expectations, and clinical infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific influence access and commercialization

Regional dynamics materially influence clinical trial enrollment, regulatory approaches, pricing expectations, and patterns of care, and a nuanced understanding of geographic variation is essential for global strategy. In the Americas, diverse payer models and a strong emphasis on innovation influence adoption trajectories for novel therapies, while real-world evidence generated in this region often informs payer decisions and guideline updates. Moreover, the concentration of leading academic centers supports early-phase trial activity, facilitating rapid evaluation of promising combinations and biomarkers.

In Europe, Middle East & Africa, heterogeneous regulatory environments and variations in reimbursement approaches require tailored access plans that reflect national-level health technology assessment processes and budgetary constraints. Stakeholders operating across these regions must align dossier development and health economic modelling with local evidentiary needs to navigate reimbursement pathways successfully. Transitioning eastward, the Asia-Pacific region spans mature health systems alongside emerging markets, each with distinct expectations regarding clinical evidence, pricing, and local manufacturing. Governments and private payers in this region are increasingly investing in oncology infrastructure and biomarker testing capacity, which in turn shapes demand for targeted therapies.

Taken together, regional strategies should be informed by local clinical practice patterns, regulatory timelines, and payer evidence requirements. Cross-border initiatives that leverage local partnerships, foster capacity building, and adapt commercial models to national contexts can accelerate access and optimize patient outcomes while respecting the unique operational realities of each geography.

Company strategic postures and partnership models that accelerate development, global reach, and access for innovative kidney cancer therapies

Company-level dynamics reflect diverse strategic postures ranging from focused biologics specialists to diversified pharmaceutical organisations pursuing integrated oncology portfolios. Leading developers tend to concentrate investments in combination science, biomarker-driven indications, and real-world outcomes programs designed to demonstrate durable clinical benefit and cost-effectiveness to payers. At the same time, midsized and emerging companies frequently pursue niche indications or innovative delivery platforms to carve differentiated value propositions and attract strategic partnerships or licensing opportunities.

In addition, the competitive environment incentivizes collaboration across the ecosystem: alliances between biotech innovators and established commercial organisations can accelerate late-stage development and expand global reach. Manufacturing partnerships and contract development collaborations are likewise crucial for managing the complex supply chains associated with biologics and cell therapies. Moreover, companies that invest early in post-approval evidence generation, patient support programs, and streamlined access solutions tend to enable smoother adoption of new therapies in diverse care settings.

Strategically, management teams should prioritize integrated planning that aligns clinical development, regulatory engagement, and market access activities. This approach reduces time-to-adoption risk, positions products competitively in crowded treatment landscapes, and enhances the potential for sustainable patient access across heterogeneous healthcare systems.

Practical strategic actions industry leaders should take to align biomarker development, evidence generation, supply resilience, and commercial execution for durable impact

Industry leaders should adopt a multi-dimensional playbook that aligns scientific priorities with pragmatic commercialization and access tactics, enabling rapid translation of promising therapies into sustainable clinical use. First, executives must prioritize biomarker-driven development and invest in companion diagnostics to ensure patient selection strategies are robust and clinically actionable. This alignment reduces development risk and strengthens the evidentiary case for reimbursement by demonstrating targeted benefit in defined patient subsets.

Second, organizations should proactively design post-approval evidence programs and real-world outcome studies that address payer and clinician questions about durability, safety in broader populations, and comparative effectiveness. These programs should be integrated with health economic models to support pricing and reimbursement dialogues. Third, resilience in supply chain and sourcing should be established through diversification, strategic partnerships, and contingency planning to mitigate the operational impact of external cost pressures. Fourth, companies must adapt commercial models to accommodate shifts in route of administration and care setting, ensuring that patient support services, specialty pharmacy strategies, and provider education programs are coordinated to facilitate uptake.

Finally, leaders should pursue collaborative models with academic centers, payers, and patient advocacy groups to co-create evidence, enhance trial enrollment, and align on value frameworks. By executing this set of actions, organizations can accelerate adoption while maintaining focus on patient outcomes and payer-relevant value propositions.

An evidence-driven research methodology combining literature synthesis, expert consultations, real-world data review, and scenario-based analytical rigor to validate insights

The research underpinning this report combined a multi-source evidence framework with rigorous analysis to ensure comprehensive, reproducible findings. Primary data inputs included systematic reviews of peer-reviewed clinical literature, regulatory decisions, and guidance documents, supplemented by an examination of real-world evidence sources and practice-pattern analyses. These elements were synthesized to map therapeutic evolution, clinical adoption trends, and the operational implications for development and commercialization.

In parallel, expert consultations with oncologists, health economists, reimbursement specialists, and supply chain professionals informed interpretation and contextualization of findings. These engagements helped validate assumptions about clinical practice, unmet needs, and payer considerations, and they guided prioritization of strategic recommendations. Analytical approaches incorporated qualitative synthesis of clinical and policy trends alongside scenario-based assessments of operational risks, ensuring that conclusions remain robust across plausible market conditions.

Finally, the methodology emphasized transparency and reproducibility: data sources and analytical frameworks were documented to enable stakeholders to trace insights back to original evidence streams. This structured approach supports confident decision-making and facilitates targeted follow-up analyses tailored to specific organizational questions.

Concluding synthesis emphasizing the need to combine innovative science with disciplined commercialization and regional strategies to improve patient outcomes

In conclusion, the kidney cancer therapeutics environment is characterized by rapid innovation, shifting care paradigms, and increasing emphasis on evidence that demonstrates meaningful clinical and economic value. Progress in targeted therapies and immuno-oncology has expanded therapeutic options across multiple renal cancer types, while evolving delivery formats and site-of-care dynamics continue to influence adoption. At the same time, operational considerations such as supply chain resilience and regional regulatory variance are central to enabling access and sustaining therapy continuity.

For stakeholders, the imperative is to integrate scientific ambition with pragmatic commercialization and access planning. This requires early alignment on biomarker strategies, investment in post-approval evidence generation that resonates with payers and clinicians, and proactive supply chain planning to mitigate external cost pressures. Moreover, regional differentiation in regulatory, payer, and clinical practice contexts mandates tailored strategies that reflect local realities while leveraging global capabilities.

Taken together, a balanced strategy that couples innovative science with disciplined execution will position organizations to deliver meaningful improvements in patient outcomes while navigating the complexities of a rapidly transforming therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Kidney Cancer Drugs Market, by Cancer Type

  • 8.1. Renal Cell Carcinoma
  • 8.2. Renal Sarcoma
  • 8.3. Transitional Cell Carcinoma
  • 8.4. Wilms Tumor

9. Kidney Cancer Drugs Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Hormone Therapy
  • 9.3. Immunotherapy
  • 9.4. Novel Therapies
  • 9.5. Targeted Therapy

10. Kidney Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Kidney Cancer Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Kidney Cancer Drugs Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Kidney Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Kidney Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Kidney Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Kidney Cancer Drugs Market

17. China Kidney Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agensys, Inc.
  • 18.6. Aravive, Inc.
  • 18.7. Arrowhead Pharmaceuticals, Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. AVEO Pharmaceuticals, Inc. (an LG Chem company)
  • 18.10. Bayer AG
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Calithera Biosciences, Inc.
  • 18.13. Cytokinetics, Incorporated
  • 18.14. Eisai Co., Ltd.
  • 18.15. Exelixis, Inc.
  • 18.16. Ipsen SA
  • 18.17. Johnson & Johnson
  • 18.18. Merck & Co., Inc.
  • 18.19. Nektar Therapeutics
  • 18.20. Novartis AG
  • 18.21. Peloton Therapeutics, Inc. (a Merck & Co., Inc. company)
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG (F. Hoffmann-La Roche Ltd)
  • 18.24. Surface Oncology, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)